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Abstract
The normal function of poly (ADP-ribose) polymerase-1 (PARP-1) is the routine repair of DNA damage by adding
poly (ADP ribose) polymers in response to a variety of cellular stresses. Recently, it has become widely appreciated
that PARP-1 also participates in diverse physiological and pathological functions from cell survival to several forms
of cell death and has been implicated in gene transcription, immune responses, inflammation, learning, memory,
synaptic functions, angiogenesis and aging. In the CNS, PARP inhibition attenuates injury in pathologies like cere-
bral ischemia, trauma and excitotoxicity demonstrating a central role of PARP-1 in these pathologies. PARP-1 is also
a preferred substrate for several ‘suicidal’ proteases and the proteolytic action of suicidal proteases (caspases, cal-
pains, cathepsins, granzymes and matrix metalloproteinases (MMPs)) on PARP-1 produces several specific proteoly-
tic cleavage fragments with different molecular weights. These PARP-1 signature fragments are recognized
biomarkers for specific patterns of protease activity in unique cell death programs. This review focuses on specific
suicidal proteases active towards PARP-1 to generate signature PARP-1 fragments that can identify key proteases
and particular forms of cell death involved in pathophysiology. The roles played by some of the PARP-1 fragments
and their associated binding partners in the control of different forms of cell death are also discussed.
Introduction
PARP-1 is a nuclear protein with a wide range of phy-
siological as well as pathological functions. Initially iden-
tified as an enzyme that performs central roles in the
repair of damaged DNA, PARP-1 participates in initiat-
ing base excision repair (BER) (PARP-1
-/- cells have
impaired BER activity) [1,2], nucleotide excision repair,
single strand base repair mediated by DNA ligase III,
XRCC1, poly nucleotide kinase, proliferating cell nuclear
antigen and flap endonuclease-1, and contributes to
double strand base (DSB) repair in an alternate non-
homologous end joining pathway with DNA ligase III
[3-6]. Interestingly, over-expression of PARP-1 or DNA
binding domain of PARP-1 (lacking catalytic domain)
decreased DSB repair, indicating that its enzymatic
activity is not essential in all repair processes [7]. Many
additional functions of PARP-1 have now been demon-
strated in biochemical and molecular signaling [8].
Apart from its role in repairing DNA damage, PARP-1
also plays important roles in transcription, cardiac
remodeling, vasoconstriction, regulation of astrocyte and
microglial function, long term memory and aging [9-17].
Progressive DNA damage and decreased PARP-1 activity
in aging neurons eventually leads to programmed neuro-
nal death and loss of memory consolidation. PARP-1’s
role in neuronal BER indicates that it may influence
age-related memory deficits and dementia. Further,
over-expression of PARP-1 and telomeric repeat binding
factor-1 were also associated with age dependent telo-
mere shortening in ‘Duchenne muscular dystrophy’ [18].
PARP-1 influences ~3.5% of the total transcriptome of
embryonic liver and stem cells and regulates ~60-70% of
genes controlling cell metabolism, cell cycle and tran-
scription. Gene expression is dysregulated in PARP-1
deficient fibroblasts and PARP-1 deficient mice are more
susceptible to skin diseases [19-21] reflecting the role of
PARP-1 against UV-induced DNA damage. PARP-1 also
interacts with, and modulates the function of several
transcription factors including NF-B, NFAT, E2F-1, and
ELK-1 [22-28]. PARP-1 is also involved in modulating
endothelial cell adhesion molecule expression (e.g. during
atherogenesis) via its binding partner NF-B [16,29,30].
PARP-1, 2 and 3 can activate CNS immune responses by
promoting astrocyte production of inflammatory
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kine CCL2 after challenge with Staphylococcus aureus,a
common CNS infectious agent [14].
The PARP family consists of 17 members which have
different structures and diverse functions in cells [31].
PARP-1, the canonical representative of this superfamily
has become the major focus of research due to its multi-
faceted roles in many cellular activities. This review
focuses on the interactions between PARP-1 and suici-
dal proteases like caspase, calpain, granzyme, and
MMPs that lead to the formation of PARP-1 proteolytic
signature fragments associated with particular pathologi-
cal conditions.
PARP-1 is an abundant nuclear enzyme with approxi-
mately 1-2 million copies in the cell which account
for ~85% of total cellular PARP activity [31-34]. Post-
translation modification involving poly (ADP-ribosyl)
ation plays a central role in cellular homeostasis [35].
Protein modifications involving phosphorylation, acetyla-
tion, methylation and poly (ADP ribosyl)ation are vital
cellular processes that are required for cell signaling,
survival and functioning [34,36-39]. This form of post
translational modification is mainly mediated by PARP-
1 which catalyzes the formation of chains approximately
200 units long linear or branched poly (ADP ribose)
units from donor NAD
+ molecules frequently linked by
esterification to glutamate, and less commonly to aspar-
tate or lysine resides on target molecules [34,40]. Poly
(ADP-ribosyl)ation is therefore an important mechanism
for maintaining genome integrity, replication, transcrip-
tion, protein degradation, differentiation and in the
repair process following DNA damage [13,34,41-43].
PARP-1 has several important domains: a 54-kD cataly-
tic domain (CD) at the carboxyl terminus that poly-
merizes linear or branched poly-ADP ribose units (from
NAD
+) on target proteins, a 46-kD DNA binding domain
(DBD) containing 2 zinc finger motifs (at the NH2 termi-
nus), and 22-kD auto-modification domain (AMD) that
functions as a target for direct covalent auto-modification
in its central region [34]. For example, high affinity bind-
ing of PARP-1 to specific DNA motifs like double-strand
breaks, cruciforms, cross-overs and nucleosomes require
the DBD for active modification [44-46]. While the 2
zinc finger motifs at the N-terminus facilitate tight bind-
ing of PARP-1 to DNA and promotes the activation of
the catalytic domain at the C-terminus, a 3
rd zinc finger
motif located between 2
nd zinc finger motif and AMD
also plays an important role in the inter-domain interac-
tions and is vital for PARP-1 enzymatic action [47].
AMD contains a BRCT fold (a motif also found in many
DNA repair proteins) that is involved in protein-protein
interactions which promotes the recruitment of
DNA repair enzymes to the site of DNA damage [48,49].
These PARP-1 domains play different roles in various
pathological cell death processes mediated by PARP-1
cleavage by suicide proteases. These suicidal proteases
(caspases, calpains, cathepsins, granzymes and MMPs)
cleave PARP-1, creating PARP-1 fragments with diverse,
exposed structural domains mediating specific forms of
cell death. The present review focuses on the different
actions of these proteases towards PARP-1, the produc-
tion of a variety of different PARP-1 signature fragments,
and the specific patterns of cell death linked with particu-
lar PARP-1 fragments.
PARP-1 and Caspases
Apoptosis, the process of programmed cell death is
essential for proper homeostatic maintenance and survi-
val in multi-cellular organisms. Physiological apoptosis
controls cell numbers, tissue and organ morphology and
patterning, and removes injured or mutated cells
[50,51]. Dysregulated apoptosis results in elevated or
decreased cell death often leading to neurodegenerative
disorders, cancer and other hyper-proliferative disorders
[52,53]. One of the most common signaling cascades
involved in apoptosis is the activation of a highly specia-
lized family of cysteinyl-aspartate proteases (caspases)
which are usually present as inactive zymogen forms.
Once activated, caspases initiate cell death by cleaving
and activating effector caspases which drive the process
of apoptosis [54]. Interestingly, recent reports have
shown the involvement of caspases not only in apopto-
sis, but also in forms of cell proliferation in a Drosophila
model. One of the 2 distinct forms of ‘apoptosis induced
compensatory proliferation’ (AICP) depends on initiator
caspase Dronc (initiator caspase in Drosophila, caspase-
9-like); the other is dependent on execution caspase
DrICE and Dcp-1 (effector caspases in Drosophila; cas-
pase-3-like) [55-58]. Moreover, apart from their primary
function in executing apoptosis, non-apoptotic functions
of caspases include hematopoiesis (erythropoiesis,
monocyte, lymphocyte differentiation, platelet matura-
tion) [59] and regulation of neuronal synaptic plasticity
in long-term potentiation [60,61]. Caspase mediated
apoptotic cell death is accomplished through the clea-
vage of several key proteins required for cellular func-
tioning and survival [62]. PARP-1 is one of several
known cellular substrates of caspases. Cleavage of
PARP-1 by caspases is considered to be a hallmark of
apoptosis [63,64]. Almost all caspases including caspase-
1, are known to modify PARP-1 in vitro [65]. Lazenbik
et al., have observed protease activity resembling inter-
leukin converting enzyme (prICE: caspase-3) which
cleaves PARP-1 after aspartate (glutamate-valine-aspar-
tate-glycine), a substrate specificity identical to one of
ICE cleavage sites in vitro to yield an 85-kD PARP-1
fragment [66]. Cleavage of PARP-1 by caspase-3 has
been implicated in several neurological diseases e.g.
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Parkinson’s disease, traumatic brain injury, NMDA-
mediated excitotoxicity and brain tumors, especially
gliomas [67-74]. Besides caspase-3, caspase-7 also
cleaves PARP-1 in vivo. The cleavage of PARP-1 by
these caspases results in the formation of 2 specific frag-
ments: an 89-kD catalytic fragment and a 24-kD DBD
[65,66]. The 89-kD fragment containing AMD and the
catalytic domain of the enzyme has a greatly reduced
DNA binding capacity and is liberated from the nucleus
into the cytosol [75]. The 24-kD cleaved fragment with
2 zinc-finger motifs is retained in the nucleus, irreversi-
bly binding to nicked DNA where it acts as a trans-
dominant inhibitor of active PARP-1. Importantly,
irreversible binding of the 24-kD PARP-1 fragment to
DNA strand breaks inhibits DNA repair enzymes (includ-
ing PARP-1) and attenuates DNA repair (also conserving
cellular ATP pools) [76-78]. Poly (ADP-ribosyl)ation of
PARP-1 following DNA breaks changes PARP-1 targeting
from caspase-3 from caspase-7 in human promyelocytic
leukemia cells (HL-60) treated with etoposide phosphate
(VP-16). However, increased caspase-3 levels (and activ-
ity) might lead to PARP-1 cleavage irrespective of its
auto-modification (by poly (ADP-ribosyl)ation) [79]. In a
similar context, Margolin et al., using the 46-kD DBD of
PARP-1 (lack which auto-modification sites) reported an
increased affinity of caspase-3 for PARP-1, indicating a
prominent role for PARP-1 automodification sites in cas-
pase-3 mediated proteolytic cleavage [65].
Under basal conditions, the primary function of
PARP-1 is to detect and repair DNA damage. However,
cells with severely damaged DNA have amplified PARP-
1 activity resulting in high NAD
+ consumption (deplet-
ing ATP pools). If unchecked, this activity inevitably
leads to passive necrotic cell death (resulting from pro-
longed ATP depletion) [80,81]. This process is blocked
by rapid cleavage and inactivation of PARP-1 by the
action of caspases [81,82]. However, insults which initi-
ate necrosis cause PARP-1 overactivation that proceeds
unchecked due to inadequate caspase activation [82-84],
lower PARP-1 cleavage and less PARP-1 24-kD frag-
ment formation. It is therefore possible that exogenous
addition of PARP-1 24-kD fragments could attenuate
PARP-1 overactivation possibly blocking cell death. Exo-
genous administration of 24-kD PARP-1 fragments
might attenuate PARP-1 overactivation and divert
necrosis towards apoptotic cell death. Taken together,
these findings suggest that the PARP-1 24-kD fragment
can also serve as a powerful therapy for CNS disorders
like cerebral ischemia where necrotic cell death predo-
minates within the infarct core. PARP-1 cleavage by cas-
pases and the resulting specific fragmentation patterns
are indicated in figure 1 and Additional file 1: Table-1.
PARP-1 and Calpains
Calpains are a family of 14 Ca
2+-activated, non-lysosomal
cysteinyl proteases active at neutral pH [85]. Of all the cal-
pain isoforms, m-calpain and μ-calpain (activated at μM-
mM Ca
2+ concentrations) are the best understood. Altera-
tions in intracellular calcium levels are known to initiate
calpain activation often exacerbating pathological condi-
tions [86]. For example, pathologic calpain activation
aggravates neurodegenerative disorders like cerebral ische-
mia, neonatal hypoxia, cerebral malaria, Alzheimer’sd i s -
ease, Parkinson’s disease, Huntington’s disease, multiple
sclerosis, and also contributes to injury in brain tumors,
such as gliomas [68-70,87-92]. Translocation of calpains to
the plasma membrane is required for optimal calpain acti-
vation. However in neurons, NMDA-mediated excitotoxi-
city involves calpain activation without a requirement for
membrane translocation [93,94]. Calpains also play promi-
nent roles in normal physiology e.g. neuron synaptic sig-
naling, myoblast differentiation, cell migration, embryonic
development (where m-calpain deficiency is embryonic
lethal) and angiogenesis [95-98]. VEGF mediated angio-
genesis involves increased Ca
2+ uptake in cells to activate
m-calpain and VEGF induced retinal angiogenesis in vitro
could be reversed by the calpain inhibitor SNJ-1945
[99,100]. Interestingly, PARP-1 inhibition also been shown
to decrease VEGF induced angiogenesis [101]. Hence,
even though calpain mediated PARP-1 proteolysis can
decrease angiogenesis; calpains might still promote angio-
genesis by augmenting VEGF expression [100] indicating
Figure 1 PARP-1 interactions with cell death proteases.P A R P - 1
cleavage by various suicidal proteases like caspases, calpain,
cathepsins and granzymes liberates fragments with specific
molecular weights and are shown in this schematic representation.
Importantly, 21-kD and 55-kD PARP-1 fragments generated by
caspase 3/7 and Gra-A respectively function as an inhibitor of PARP-
1 activity and might also play important roles in reducing necrosis
and/or parthanatos. Further, PARP-1 and PARP-1 fragment’s
involvement in various forms of cell death e.g. autophagy, necrosis
and parthanatos are also indicated.
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portional to the magnitude of calpain mediated PARP-1
proteolysis is possible. More studies are still required to
address this issue and understanding the roles played by
PARP-1, calpains and VEGFs in post-ischemic cerebral
angiogenesis is an area of drug development, particularly
for stroke therapy.
Calcium, apart from activating calpains, also promotes
PARP-1 hyper-activation through production of ROS
and peroxynitrite [102]. The anti-tumor drug b-lapa-
chone induces PARP-1 dependent cell death indepen-
dent of caspases via metabolic starvation. b-lapachone
treated cells also exhibit increased cytosolic Ca
2+ (by
release of endoplasmic reticulum Ca
2+ stores) and ROS,
resulting in PARP-1 hyper-activation. PARP-1 hyper-
activation by b-lapachone was blocked by BAPTA-AM
(a cytosolic Ca
2+ chelator) indicating that Ca
2+ induced
ROS generation leads to PARP-1 hyper-activation and
cell death [103]. Conversely, cellular Ca
2+ levels were
altered by PARP-1 in doxorubicin-induced myocardial
injury. Szenczi et al., have shown that both cardiac con-
tractile capacity and intracellular Ca
2+ loading was
reduced in doxorubicin-treated hearts, an effect blocked
by PARP-1 inhibition. These responses may be indirect
through the effects of PARP-1 on the transcription of
proteins involved in Ca
2+ handling and Ca
2+ pumps
[104]. PARP-1 has also been shown to modulate neuro-
nal mitochondrial Ca
2+ levels [105]. PARP-1 activity
raises intra-mitochondrial Ca
2+ levels, activating μ-cal-
pain to release mitochondrial apoptosis inducing factor
(AIF) [106]. However, because activated calpains med-
iate proteolytic breakdown of PARP-1, the temporal
association of PARP-1 and calpain in AIF nuclear trans-
location may be phase-dependent, more studies will be
required to address this. The roles of PARP-1 in Ca
2+
handling and excitotoxicity point towards pleiotropic
functions of PARP-1 in pathological settings.
Calpains play crucial roles in both caspase-dependent
and independent forms of apoptotic cell death and are
key mediators of necrotic cell death [107,108]. A variety
of cellular insults can activate calpains including
increased cytosolic Ca
2+, decreased calpastatin levels,
interactions with calpain activator protein, phospholi-
pids, and caspase activation [109-112]. Several cell sub-
strates have been identified as calpain targets resulting
in proteolytic breakdown to signature fragments of spe-
cific molecular weights [69,91,113]. Appearance of dis-
tinctive cleavage (’signature’) fragments is considered to
represent specific forms of calpain activation. Among
the various cellular substrates of calpain, PARP-1 clea-
vage gives rise to a 40-kD N-terminal fragment in neu-
roblastoma cells (SH-5YSY) challenged with maitotoxin
[114]. μ-calpain isolated from calf thymus generates
~40-70-kD N-terminal PARP-1 fragments [115]. Calpain
induced 40-kD fragments were recognized by both C-2-
10 and N-20 antibodies (which detect PARP-1 fragments
bearing the N-terminal domain/DBD). Depending on
observed molecular weight and immunoreactivity it can
be presumed that this PARP-1 fragment might have
DBD domain, but not AMD or catalytic domains.
Whether this 40-kD fragment plays any role in PARP-1
auto-modification (as shown in studies on the 24-kD
PARP-1 DBD fragment) is not yet known. This fragment
appears specifically when PARP-1 is digested with cal-
pain, and μ-calpain inhibitor reduces its appearance,
indicating that it is a μ-calpain-specific PARP-1 signa-
ture fragment. We don’t know whether this fragment
represents a byproduct formed during calpain mediated
necrotic cell death or if it can actively attenuate necro-
sis. Based on the findings that the zinc finger motifs
present in the DBD domain of PARP-1 can facilitate
irreversible binding of DBD to DNA nicks and promote
transdominant inhibition of activated PARP-1, the
appearance of this fragment would be consistent with its
ability to attenuate PARP-1 activity during calpain
mediated necrosis. Calpains are known to mediate apop-
totic cell death. Whether this fragment appears only
during necrotic conditions or also during calpain-
mediated (caspase independent) apoptosis is unknown.
Future studies on the molecular biology of this fragment
and its roles in specific cell death pathways will be
needed to determine its role in neuronal pathologies. So
far, these fragments remain most convincingly related to
necrotic modes of cell death mediated by calpain.
Apart from PARP-1, caspase-7 has also been shown to
be a target of μ-calpain. μ-calpain cleaves caspase-7 to
active 18.5 and 17.2-kD fragments. This calpain gener-
ated caspase-7’s 17.2-kD fragment is ~18 fold more
active than the 20-kD caspase-3 generated fragment of
caspase-7 [116]. Whether these fragments are involved
in preferential PARP-1 processing over caspase-3 is not
yet known. PARP-1 cleavage by calpains results in speci-
fic fragmentation patterns which are described in figure 1
and Additional file 1: Table-1.
PARP-1 and Cathepsins
Lysosomes were initially des c r i b e da sp a r t i c i p a n t si n
catabolic autophagic cell death when exhausted or
damaged organelles were digested and secreted into the
cytoplasm [117]. Lysosomes and lysosomal proteases
also participate in apoptotic and necrotic forms of cell
death [118-120]. Cathepsins belong to the family of lyso-
somal proteases which are active at acidic pH. These are
stored in lysosomes as inactive precursors and activated
by stimuli that lower cell pH, resulting in the release of
their catalytically active forms which cleave multiple tar-
gets [121]. Cathepsins can initiate apoptotic cell death
independent of caspases, and are known to be key
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gic protease levels can aggravate post-ischemic neuro-
pathologic with injury [122]. Recent reports clearly show
that the biogenesis of lysosomal cathepsins is required
for necrotic cell death [118]. One of the important dif-
ferences between apoptotic and necrotic forms of cell
death is the protein synthesis pattern. During apoptotic
cell death, normal protein synthetic processes are
rapidly shut down, an event which conserves ATP,
which is used to accomplish apoptosis. Conversely, the
persistence of protein synthesis during necrotic cell
death can deplete energy reserves accelerating necrotic
cell death [118-123]. Since lysosomal biogenesis is
required for necrotic cell death, persistent protein synth-
esis might help in lysosomal-cathepsin synthesis, which
eventually spills into the cytosol, cleaving PARP-1 and
contributing to cell death [118,123]. However, the
numerous targets and temporal specificities of cathe-
psins and PARP-1 contributing to cell death mechan-
isms require further study.
Cathepsins are a large family of lysosomal enzymes
comprising 11 cysteinyl cathepsins (and aspartyl pro-
tease cathepsin-D) which are also active at neutral pH.
These have a relatively short biological half-life, but
acidification of the cytosol will increase their residence
time. However, due to the abundance of cathepsin B, D
and L, these are most often used as markers for the
involvement of lysosomes in particular forms of cell
death [119]. Cathepsins B, S and G are also involved in
tumor invasion (glioblastoma multiforme, breast cancer
bone metastasis and colorectal tumors), endothelial pro-
liferation and in angiogenesis (via TGF-b,V E G Fa n d
MCP-1) [124,125]. It is important to note that necrosis
is common in tumor tissue and is usually accompanied
by PARP-1 hyper activation. Considering that PARP-1
inhibition reduces angiogenesis, it is possible that hyper-
activated PARP-1 might in part drive tumor angiogen-
esis and metastasis. Cathepsins and TGF-b are also
involved in caspase-independent PARP-1 cleavage (an
~85-kD caspase independent PARP-1 fragment is pro-
duced by TGF-b) [126]. How these mediators drive
angiogenesis or can be used in diagnosis or therapy
needs further study.
Moreover, TGF-b and cathepsin-G mediated angio-
genesis depends on the upregulation of VEGF [124].
Hence, breakdown of PARP-1 (which would reduce the
angiogenic program) might be balanced by increased
VEGF production by cathepsins. It is important to iden-
tify whether the breakdownp r o d u c t so fP A R P - 1p r o -
duced by calpains or cathepsins can substitute for the
PARP-1 function in angiogenic programs. More impor-
tantly, the effect of transdominant inhibition of PARP-1
by DBD in modulating angiogenic programs is worth
investigating. These findings indicate that angiogenesis
associated with PARP-1 signaling is highly complex,
tightly controlled and pathology specific. The extent of
PARP-1 and PARP-1 cleavage products’ involvement in
modulating angiogenic programs has yet to be fully
determined.
Cysteine cathepsins also share several common targets
along with PARP-1. PARP-1 was initially found to pro-
duce a 50-kD fragment (necrotic fragment) during
necrotic cell death. Necrotic PARP-1 fragmentation was
later characterized and the appearance of these PARP-1
fragments shown to be mediated by lysosomes and lyso-
somal specific proteases cathepsin-B, -D and -G. During
necrosis, induced by H2O2, 10% ethanol, HgCl2, lysoso-
mal extracts and cathepsin-B, PARP-1 gave rise to frag-
ments ranging from 42-89-kD [127]. Cathepsin-B and D
produce active PARP-1 fragments with molecular weights
of 55-kD and 42-kD, similar to the fragments obtained
from the lysosomal extracts. Inactive PARP-1 fragments
with molecular weights of 74 and 62-kD are also liber-
ated by the action of these proteases. Cathepsin-G,
another lysosomal protease, also produced a similar frag-
mentation pattern, but with lower intensity (requiring
longer incubation periods vs. cathepsin-B and D). More-
over, the 89-kD PARP-1 fragment which appears during
apoptotic cell death could also be produced by cathepsin-
B and D, but is not generated by cathepsin-G [127].
Cathepsin specific PARP-1 fragmentation patterns are
shown in figure 1 and Additional file 1: Table-1.
PARP-1 and granzymes
The immune system maintains an internal homeostasis
by recognizing and reacting to foreign particles, abnor-
mal or infected cells to restrict their further persistence
and penetration within the host. Immune processes use
highly specialized and cell-specific mechanisms and
molecules to accomplish this. Induction of cytotoxicity
in target cells is a multifactorial process accomplished
by cytotoxic T lymphocytes (CTLs) and natural killer
(NK) cells that secrete toxic and lytic proteases of the
serine protease family (granzymes), perforins and granu-
lysin [128]. About 90% of cytolytic granules stored in
CTLs and NK cells contain granzymes. Granzymes are
subdivided into 3 categories based upon their enzymatic
similarity to chymotrypsin (chymase locus), trypsin
(tryptase locus) and those that cleave after unbranched
hydrophilic residues particularly after methionine (Met-
ase-locus). A total of 10 granzymes have been found in
the mouse (granzymes A-G and K-M), 7 in rats (A, B,
C, I, J, K and M) and 5 in humans (granzymes A, B, H
which are specific to human, M and tryptase2/gran-
zyme-3). Human homologs of granzymes C-G have still
not been found [129].
Granzymes are secreted from cytotoxic cells upon
recognizing their target cells, with several physiological
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granzymes promote extracellular matrix degradation,
lymphocyte migration, cytokine production and attenu-
ate tumor cell migration[130]. Pathological granzyme
actions are important in inflammatory vascular disorders
(atherosclerosis, transplant vascular disease, systemic
lupus erythrematosus, autoimmune vasculitis) [131-133],
chronic allergic or autoimmune diseases (arthritis,
chronic allergic asthma, hypersensitive pneumonitis)
[134-136] and neurodegenerative disorders (spinal cord
injury, cerebral ischemia, multiple sclerosis, brain
tumors like gliomas) [68,70,137-139]. Of the family of
granzymes, granzyme-B (Gra-B) is considered to be the
most potent apoptogenic molecule, even though gran-
zyme-A (Gra-A) and Gra-B are the most abundant pro-
teases in lytic granules [140]. Other members of the
granzyme family perform functions outside of apoptosis
and independent of caspases.
Gra-A has been shown to induce caspase-independent,
but morphologically indistinguishable apoptosis. Induc-
tion of Gra-A mediated apoptosis involves activation of
Gra-A activated DNase to induce single stranded nicks
in DNA, breakdown of oxidative repair protein ‘apuri-
nic/apyrimidinic (AP) endonuclease’ (APE), KU-70 and
mitochondrial complex I protein [141-144]. Apart from
lamin, which is the common substrate for Gra-A, Gra-B
and caspase-3, PARP-1 is also cleaved by these 3 pro-
teases resulting in different fragmentation patterns
[66,145-147]. Importantly, even though PARP-1 is a
direct substrate for Gra-A it can only cleave intracellular
PARP-1 in the presence of perforins [145]. This finding
also underscores the necessity of perforin for Gra-A to
enter the cell to execute cell death, unlike Gra-B. Gra-A
activity towards PARP-1 results in its breakdown with
high efficiency after Lys
498 leading to the formation of a
C-terminal 55-kD inactive fragment and an N-terminal
fragment of similar molecular weight. Cleavage of
PARP-1 at Lys
498 residue by Gra-A results in decreased
auto-modification of PARP-1, poly (ADP ribosyl)ation
and DNA repair. Gra-A mediated formation of N-term-
inal active 55-kD PARP-1 (after Lys
498) may cause cells
to undergo caspase-independent apoptotic cell death,
rather than necrotic cell death, by decreasing the effi-
ciency of ADP ribosylation. Since Gra-A cleaves oxida-
tive repair enzymes and increases ROS production, it
will indirectly activate PARP-1; decreased poly (ADP-
ribosyl)ation counteracts these deleterious effects [145].
However, whether Gra-A has any role in ‘parthanatos’
(cell death mediated by poly (ADP ribose) polymers) or
necrosis is a topic for future studies. Even though cathe-
psin-B and Gra-A produce similar 55-kD C-terminal
PARP-1 fragments, they differ in recognized cleavage
sites. For example, cathepsins cleave PARP-1 at leu-
cine
525 residues, but Gra-A cleaves preferentially at
lysine
498 [127,145] resulting in the formation of N-term-
inal fragments that attenuate PARP-1 depletion of ATP.
Unlike Gra-A, cathepsin mediated PARP-1 cleavage at
Leu
525 results in the formation of 55-kD active C-term-
inal and 62-kD inactive N-terminal fragments [127].
Consequently cleavage-site specificity plays a major role
in the generation of fragments derived from particular
domains that differentially modulate forms of cell death
(apoptosis vs. necrosis).
Gra-B was the first serine protease discovered to
cleave PARP-1 during induction of cell death. Gra-B can
translocate into cells in both a perforin-dependent and
independent manner. Unlike Gra-A, Gra-B shares simi-
lar substrate specificity with caspase-3 (i.e. it cleaves
after aspartate residues) and induces more rapid cell
death [140]. Further, Gra-B can mediate apoptosis inde-
pendent of caspases, or by directly activating caspases or
indirectly by activating Bid [148,149].
Apart from various other cellular substrates, Gra-B
cleaves PARP-1 into 64-kD and 61-kD N-terminal frag-
ments and C-terminal 54-kD and 42-kD fragments. Of
these, the 54-kD and 42-kD PARP-1 fragments were
found to be catalytically active, while the 64-kD and 61-
kD fragments were inactive. This was mainly based on
t h ep r e s e n c eo fi n t a c tc a t a l y t i cd o m a i na tt h eC - t e r m i -
nus [147]. Using activity western blots, it has been
shown that the fragments 54-kD and 42-kD fragments
are catalyticall ya c t i v e .T h e4 2 - k Df r a g m e n tw a s
detected in activity western blots but not when immu-
noblotted with N-terminus specific antibody, indicating
that it is C-terminus fragment. N-terminal analysis of
the 54-kD fragment has shown that the cleavage site fol-
lows Asp
537. It was further suggested that the appear-
ance of 42-kD fragment is due to the secondary
cleavage of 54-kD and 61-kD fragment was due to the
secondary cleavage of 64-kD fragment [147].
The appearance of PARP-1 fragments with multiple
molecular weights clearly distinguishes these proteases
from each other, and suggests the participation of speci-
fic proteases during different phases and forms of
p a t h o l o g y .T h ep r e s e n c eo fs o m eP A R P - 1f r a g m e n t s ,
like the 50-kD and 55-kD, which can be formed by
either necrotic cathepsins or by Gra-A, need to be care-
fully interpreted [127,145]. The PARP-1 fragments cre-
ated by granzyme action are indicated in figure 1 and
Additional file 1: Table-1. Based on the roles of PARP-1
in angiogenesis, whether Gra-B cleavage of PARP-1 and
the resulting PARP-1 fragments have any role in modu-
lating angiogenesis during forms of neurodegeneration
is a potential opportunity for therapy.
PARP-1 and matrix metalloproteinases
MMPs are a family of 28 zinc-dependent endopeptidases
that play significant roles in angiogenesis, embryogenesis
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myocardial ischemia, cerebral ischemia, and athero-
sclerosis [150-152]. Within this family of MMPs, MMP-
2 has recently been shown to be capable of cleaving
PARP-1. Kwan et al. have reported that MMP-2 along
with MMP-9 is present in the nuclear fraction of heart
and liver, and is able to cleave PARP-1 in a concentra-
tion dependent manner. Cleavage of PARP-1 by MMP-2
produces a 66-kD and a >48-kD fragment (seen in silver
stained gels and western blotting) [153] which differ in
their appearance. MMP-2 produced a 66-kD PARP-1
fragment in a concentration-dependent fashion whereas
there was no difference in levels of other >48-kD forms
from control conditions observed in silver stained gels.
Interestingly western blot analysis did not show any 66-
kD PARP-1 fragments but showed an increase in >48-kD
fragments in a concentration-dependent fashion. The
MMP inhibitors TIMP-2 and doxycycline were able to
block PARP-1 degradation to a 66-kD fragment. The rea-
son for the appearance of a prominent ~66-kD fragment
in TIMP-2 treated conditions and a faint band of the
same molecular weight in doxycycline treated samples is
curious. Why this fragment is specifically detected in
MMP-2 inhibited samples is also unclear. Though the
differences in the appearance of >48-kD and 66-kD frag-
ments may relate to the PARP-1 antibody used (either C-
terminus or N-terminus specific), the reason for the
appearance of ~66-kD fragment in samples with inhib-
ited MMP-2 (but not in untreated controls) are unclear.
MMPs actions are modulated by the cytokines and
endogenous MMP inhibitors in both pro- and anti-
angiogenic programs affecting extracellular and base-
ment membrane remodeling [154]. MMP-2 is known to
be a key protease involved in neovascularization, and
MMP-2
-/- mice show defects in neovascularization. Con-
versely, MMP-9 may limit collagenase-induced intracer-
ebral hemorrhage [155,156]. Moreover, conditioned
medium enriched in MMP-2 and 9 (from mouse brain
endothelial cells) increases the migration of neural pre-
cursor cells to sites of brain injury via ERK
1/2 and PI3/
AKT signaling [157]. However, several CNS pathologies
such as cerebral ischemia, multiple sclerosis and Devic’s
neuromyelitis optica are also associated with increased
MMP-2 and-9 levels and MMP-9 inhibition is beneficial
against cerebral ischemia [151,158]. Nicolescu et al.,
have recently reported that PARP-1 inhibitors can also
inhibit MMPs [159], indicating that at least part of the
protection afforded by PARP-1 inhibitors during stroke
might be due to MMP inhibition. PARP-1 inhibition
undoubtedly rescues cells from necrotic cell death, but
the role(s) played by MMP inhibition in stroke clearly
deserve further study.
Although acute PARP-1 and MMP inhibition may effec-
tively attenuate ischemic stroke, the roles of MMPs in
neuronal progenitor migration, and PARP-1’sr o l ei n
angiogenesis programs during restitution need some clari-
fication. Importantly, whether 66-kD and >48-kD PARP-1
fragments produced by MMP proteolysis have activity or
modulate PARP-1 activity is still unknown. Because PARP-
1 also regulates angiogenesis, the effect of PARP-1 proteo-
lysis by MMPs during angiogenesis may be important to
investigate for cancer and chronic inflammation therapy.
Conclusions
The molecular mechanisms involved in balancing life and
death decisions controlled by PARP-1 are highly complex
and incompletely understood. A delicate PARP-1 equili-
brium exists within cells where any deviation, either
hyper- or hypo-activity can induce or exacerbate pathol-
ogy. Many related proteases including caspases, calpains,
cathepsins, granzymes and MMPs also directly and indir-
ectly mediate the effects of PARP-1 in these phenomena.
Recent reports indicate that PARP-1 contributions to cell
death are insult- and context-dependent. PARP-1 can
also promote tissue survival by shifting the balance of cell
death programs between autophagy and necrosis. PARP-1’s
role in driving autophagy from necrosis is distinctive from
its classical role and highlights its importance in cell survi-
val decisions. It also points out an important potential
application through which modulation of PARP-1 may be
applied therapeutically. Because of PARP-1’sd u a ln a t u r ei n
life: death control, PARP inhibitors should be used with
great caution. Furthermore, physiological and pathological
roles of poly (ADP-ribosyl)ation in parthanatos and long
term memory suggest that prolonged inhibition of PARP-1
may be ultimately deleterious. Conversely, the 24-kD N-
terminal PARP-1 apoptotic fragment that attenuates necro-
tic cell death might eventually be developed for therapy.
The appearance of specific PARP-1 fragments will not only
help us understand the involvement of specific cell death
proteases in particular processes, but also different types of
cell death. These recent findings clearly indicate that a
great deal remains be defined about PARP-1, the roles of
its fragments and the specific molecular mechanisms they
regulate during various forms of cell death.
Additional material
Additional file 1: Table -1. PARP-1 signature fragments. Action of
various proteases results in the generation of PARP-1 fragments with
specific molecular weights that can be correlated with the action of
specific proteases. PARP-1 signature fragments generated by various
proteases are listed above.
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